Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone undecanoate are provided.

Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone undecanoate are provided.

Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

Abstract: The present invention generally relates to methods and compositions for the treatment of overweight or obese individuals. In particular, the invention relates to reducing adiposity of an overweight or obese individual. The present invention provides a method for reducing adiposity or treating obesity in an individual, the method comprising inhibiting TCPTP and/or PTP1B in the hypothalamus of the individual, thereby reducing adiposity or treating obesity in the individual.

Abstract: Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in-vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.

Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

Abstract: The present invention relates to the use of derivatives of salicylic acid for the treatment of diseases or conditions linked to GO and/or PRODH2 enzyme activity, in particular diseases linked to an excess of oxalate, and for the treatment of patients with renal insufficiency (uremia or azotaemia) receiving haemodialysis or peritoneal dialysis, in particular patients treated with ascorbic acid (vitamin C), which is metabolised to oxalate, or patients with fibromyalgia and vulvar pain.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Abstract: The invention relates to BODIPY derivatives of Formula (I): that bear one or more functional groups which in the photochemical reaction upon irradiation with visible light undergo deamination and deliver quinone methides. Furthermore, the invention relates to the antiproliferative activity of BODIPY derivatives and their use for pharmaceutical applications and for fluorescent labeling, particularly for labeling proteins.

Abstract: The present invention relates to a long-circulating liposome modified with c(RGD-ACP-K). The present invention pertains to the field of pharmaceutical preparations, in particular to the field of targeted pharmaceutical preparations. More specifically, the present invention relates to a long-circulating liposome, the surface of the liposome being modified with c(RGD-ACP-K), and the liposome comprising doxorubicin or a pharmaceutically acceptable salt thereof such as doxorubicin hydrochloride as an anti-cancer active agent. The long-circulating liposome can targetedly deliver the anti-cancer active agent into tumor neovascular endothelial cells and tumor cells and can prolong the circulation time of the liposome in vivo, thereby enhancing the therapeutic effect of anti-tumor medicaments.

Abstract: Disclosed is a preparation of Pulsatilla saponin B4 for injection, comprising Pulsatilla saponin B4 and a pharmaceutically acceptable excipient. The preparation is an aqueous injection or a lyophilized powder injection, more preferably a lyophilized powder injection. Methods for preparing the Pulsatilla saponin B4 aqueous injection and the Pulsatilla saponin B4 lyophilized powder injection comprise dissolution, fluid preparation, filtration and other steps. The preparation of Pulsatilla saponin B4 for injection has a low effective dose for reversing renal injury caused by cisplatin, significantly improves the medication safety of Pulsatilla saponin B4, and is expected to provide a new option for the clinical treatment of renal injuries and renal failure.

Abstract: The present disclosure discloses carbohydrate derivatives used for surface modification of immune cells, use thereof, and method thereof. The carbohydrate derivatives are 9-carbon monosaccharide sialic acid derivatives modified at C9 position by targeting substituents. The surfaces of the immune cells (T cells, NK cells, macrophages, DC cells, B cells, or granulocytes) is modified by the carbohydrate derivatives to obtain modified immune cells, so that the modified immune cells can be used for treatment of tumors or other diseases to obtain good effects.

Abstract: This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.

Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Abstract: A formulation for a dietary supplement includes standardized extracts of astragalus root, phlorizin, root bark of white mulberry, olive leaf, and bitter melon. The formulation may further include chromium, 2-deoxy-D-glucose, biotin, vitamin D and vitamin C. A method of controlling postprandial blood glucose includes administering the formulation for the dietary supplement to a patient.

Abstract: This invention relates to a combination of 2?-Deoxy-2?,2?-difluoro-D-cytidine-5?-O-[phenyl (benzoxy-L-alaninyl)] phosphate) (NUC-1031) and carboplatin, or other forms of platinum, and the use of the combination in treating cancer patients selected based on the patient's cancer's response to platinum. In particular the invention concerns the treatment of patients that have platinum sensitive cancers or platinum partially sensitive cancers.

Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.

Abstract: The present invention provides methods and compositions for controlling cardiac fibrosis and heart remodeling in a subject via modulating the expression of one or more lncRNA associated with cardiac-specific super-enhancers (SEs).

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: The present invention relates, in part, to methods of generating immune responses in subjects that have a likelihood of developing cancer.

Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.

Abstract: Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

Abstract: The present invention concerns compositions and methods related to approaches to render ineffective Thl T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. In particular embodiments, tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Thl immunostimulaotyr/activating signal.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

Abstract: Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or a polyomavirus infection.

Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Provided are soluble RAGE-secreting stem cells and a medicinal use thereof in preventing and/or treating Alzheimer's disease.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis comprising exosomes isolated from adipose tissue-derived stem cells as an active ingredient. The exosomes isolated from the adipose tissue-derived stem cells according to the present invention can facilitate osteogenesis and enhance bone density, and therefore it can be useful for prevention or treatment of osteoporosis.

Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

Abstract: The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K+) channel activator at a dosage effective to restore normal brain interstitial glial K+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

Abstract: The present invention relates to a bacteriotherapy based on bacterial compositions for the treatment and/or the prevention of neurodegenerative diseases, wherein said composition comprises an effective amount of bacterial microorganisms belonging to the species Lactobacillus fermentum, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus plantarum and Lactobacillus salivarius, and mixtures thereof.

Abstract: The present invention discloses an application of Alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases, for example but not limited to, atherosclerosis related diseases, cardiovascular diseases and obesity.

Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating alopecia and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

Abstract: One kind of live bacteria preparation of bacillus coagulans, the aforesaid live bacteria preparation is in the form of tablets; such live bacteria tablet is made from the bacteria powder of bacillus coagulans HQ-1, subsequently coated with gelatin and cooled, then made with other pharmaceutical auxiliary ingredients. The preparation method of such live bacteria preparation includes the following steps: preparing the pellet core coated with the bacteria powder; preparing the gelatin solution; wrapping the gelatin solution outside the pellet core, cooling to obtain the hard capsule; preparing the powder or pill with other pharmaceutical auxiliary ingredients and syrup; pressing to form the tablets. Such live bacteria tablet can fully protect the effective ingredient bacteria powder in the stomach and intestine, allowing the coat to be melt when reaching the affected area, so as to ensure a high utilization rate of bacteria powder.

Abstract: Embodiments of the disclosure include methods and compositions related to lectin-coated bacteria of any kind and the imparted activity of being resistant to one or more antibacterial agents and or environmental conditions. In at least some cases, lectin-coated bacteria are utilized to improve a microbiome in a subject. The lectin-coated bacteria may also be employed for uptake into cells, including eukaryotic cells such as mammalian cells.

Abstract: The present invention relates to a symbiotic composition comprising a probiotic bacterial strain and a prebiotic growth medium which is specific to the growth of the probiotic bacterial strain, wherein the bacterial strain is capable of producing the same growth medium by reverse enzyme reaction. The present invention also relates to methods of producing and screening for such compositions.

Abstract: Described in the instant application are methods and compositions for support therapy in antitumor chemotherapeutic treatments, in acquired immunodeficiency syndrome treatments and in leukemia treatments. Said methods and compositions comprise a bacterial strain belonging to the species Lactobacillus pentosus and having an antiviral and an antibacterial activity, and a highly bioavailable zinc internalized in a tyndalized bacterial cell mixed with at least one rubber, and in particular an alginate and/or a gel, and in particular a gel.

Abstract: This document provides bacterial compositions. For example, bacterial compositions having a combination of different bacterial strains formulated in a manner to maintain the stability of the bacteria are provided.

Abstract: Disclosed herein is an isolated stem cell or population thereof that comprises oncolytic herpes simplex virus (oHSV). Examples of possible stem cells include mesenchymal stem cells (MSC), neuronal stem cells and induced pluripotent stem cells. Various forms of the oHSV are disclosed. Also disclosed are methods of treating brain cancer in a subject by administering the stem cells containing oHSV to the subject to deliver the oHSV to brain cancer cells in the subject. The method is for the treatment of primary brain cancer and secondary metastatic brain cancer.

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Abstract: The present disclosure provides various cyanobacterial extracts exhibiting antiviral activity to a wide spectrum of viruses, such as enterovirus (EV), respiratory syncytial virus (RSV), Human Herpesvirus (HHV), Ebola virus, porcine epidemic diarrhea virus (PEDV), and porcine reproductive and respiratory syndrome virus (PRRSV). The cyanobacterial extract is prepared from biomass of A. maxima (or Spirulina maxima). Also disclosed herein are process for preparing the cyanobacterial extract and uses of the cyanobacterial extract.

Abstract: Compositions for treatment and/or prevention of infertility include a pollen extract and/or a pistil extract primarily obtained from plants belonging to the Pinaceae and/or Poaceae family.

Abstract: The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of Actinidia chinensis. Also encompassed are methods of preparing these compositions. Further encompassed are methods of using these compositions, in particular, for treating or preventing disorders of the gastrointestinal system, including amongst others: inflammation, constipation, bowel irregularity, microbiota imbalances, irritable bowel syndrome, and inflammatory bowel disease.

Abstract: The present invention provides new unique Cannabis lines, extracts and methods for their use in anti-cancer therapies and modalities. The method includes generation of unique lines, whole plant extract preparation, treating cancer cells and normal cells with extracts in amounts sufficient to kill cancer cells while sparing normal ones. The modulation of cell proliferation, growth and death results in efficient elimination of cancer cells.